Skip Navigation

JNCI Journal of the National Cancer Institute 2001 93(1):2-4; doi:10.1093/jnci/93.1.2
© 2001 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Jordan, V. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jordan, V. C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 93, No. 1, 2-4, January 3, 2001
© 2001 Oxford University Press

EDITORIAL

Estrogen, Selective Estrogen Receptor Modulation, and Coronary Heart Disease: Something or Nothing

V. Craig Jordan

Correspondence to: V. Craig Jordan, Ph.D., D.Sc., Robert H. Lurie Comprehensive Cancer Center, Northwestern University Medical School, 303 E. Chicago Ave., Olson 8258, Chicago, IL 60611 (e-mail: vcjordan@northwestern.edu).

In terms of lifetime risk, one in three women will die of heart disease and one in six of stroke; in contrast, one in nine women will develop breast carcinoma, and only one in 25 will eventually die of it (1). It is, therefore, clear that a successful therapeutic intervention to improve death rates for coronary heart disease (CHD), however modest, will have a disproportionately large benefit on women's health. Lipid-lowering drugs produce clear-cut benefits in the primary prevention of CHD (2). Although the population currently being evaluated is primarily male, the successful treatment strategy is invariably for 5–7 years. Duration of therapy is an important consideration for a successful intervention.

Women have less heart disease than men up to the age of 50 years but catch up to men after menopause, so there has been a tendency to ascribe an elevated risk for women to . . . [Full Text of this Article]

NOTES

REFERENCES


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Nucleic Acids ResHome page
V. Bourdeau, J. Deschenes, D. Laperriere, M. Aid, J. H. White, and S. Mader
Mechanisms of primary and secondary estrogen target gene regulation in breast cancer cells
Nucleic Acids Res., January 17, 2008; 36(1): 76 - 93.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. Deschenes, V. Bourdeau, J. H. White, and S. Mader
Regulation of GREB1 Transcription by Estrogen Receptor {alpha} through a Multipartite Enhancer Spread Over 20 kb of Upstream Flanking Sequences
J. Biol. Chem., June 15, 2007; 282(24): 17335 - 17339.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
M. Lupien, M. Jeyakumar, E. Hebert, K. Hilmi, D. Cotnoir-White, C. Loch, A. Auger, G. Dayan, G.-A. Pinard, J.-M. Wurtz, et al.
Raloxifene and ICI182,780 Increase Estrogen Receptor-{alpha} Association with a Nuclear Compartment via Overlapping Sets of Hydrophobic Amino Acids in Activation Function 2 Helix 12
Mol. Endocrinol., April 1, 2007; 21(4): 797 - 816.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. J. Fabian and B. F. Kimler
Selective Estrogen-Receptor Modulators for Primary Prevention of Breast Cancer
J. Clin. Oncol., March 10, 2005; 23(8): 1644 - 1655.
[Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
V. Bourdeau, J. Deschenes, R. Metivier, Y. Nagai, D. Nguyen, N. Bretschneider, F. Gannon, J. H. White, and S. Mader
Genome-Wide Identification of High-Affinity Estrogen Response Elements in Human and Mouse
Mol. Endocrinol., June 1, 2004; 18(6): 1411 - 1427.
[Abstract] [Full Text] [PDF]